Equity | US Equity

Invesco Equally-Weighted S&P 500 Fund

Class A

Class A

  • Class A
  • Class C
  • Class R
  • Class R6
  • Class Y
Ticker: VADAX

Objective & Strategy

The fund seeks total return through growth of capital and current income.

Management team

as of 10/31/2022

Top Equity Holdings | View all

  % of Total Assets
Biogen 0.28
Schlumberger 0.27
Dexcom 0.27
Arch Capital 0.27
Netflix 0.26
Halliburton 0.25
PG&E 0.25
Gilead Sciences 0.25
APA 0.25
Phillips 66 0.25

May not equal 100% due to rounding.

Holdings are subject to change and are not buy/sell recommendations.

as of 10/31/2022 09/30/2022

Average Annual Returns (%)

  Incept.
Date
Max
Load (%)
Since
Incept. (%)
YTD (%) 1Y (%) 3Y (%) 5Y (%) 10Y (%)
NAV 07/28/1997 N/A 8.87 -13.34 -10.39 10.05 9.27 11.99
Load 07/28/1997 5.50 8.63 -18.11 -15.31 8.00 8.03 11.36
NAV 07/28/1997 N/A 8.50 -21.04 -14.02 7.13 7.48 10.86
Load 07/28/1997 5.50 8.26 -25.38 -18.75 5.13 6.27 10.24

Performance quoted is past performance and cannot guarantee comparable future results; current performance may be lower or higher. Investment return and principal value will vary so that you may have a gain or a loss when you sell shares.
 

Performance shown at NAV does not include applicable front-end or CDSC sales charges, which would have reduced the performance.

Performance figures reflect reinvested distributions and changes in net asset value (NAV) and the effect of the maximum sales charge unless otherwise stated.

as of 10/31/2022 09/30/2022

Annualized Benchmark Returns


Index Name 1 Mo (%) 3 Mo (%) 1Y (%) 3Y (%) 5Y (%) 10Y (%)
S&P 500 Equal Weight Total Return Index (USD) 9.80 -3.83 -9.86 10.62 9.82 12.61
S&P 500 Total Return Index (USD) 8.10 -5.86 -14.61 10.22 10.44 12.79
S&P 500 Equal Weight IX -9.23 -4.79 -13.53 7.68 8.02 11.47
S&P 500 Reinvested IX -9.21 -4.88 -15.47 8.16 9.24 11.70

Source: RIMES Technologies Corp.

Source: RIMES Technologies Corp.

An investment cannot be made directly in an index.

Expense Ratio per Prospectus

Management Fee 0.11
12b-1 Fee 0.25
Other Expenses 0.16
Interest/Dividend Exp N/A
Total Other Expenses 0.16
Acquired Fund Fees and Expenses (Underlying Fund Fees & Expenses) N/A
Total Annual Fund Operating Expenses 0.52
Contractual Waivers/Reimbursements N/A
Net Expenses - PER PROSPECTUS 0.52
Additional Waivers/Reimbursements N/A
Net Expenses - With Additional Fee Reduction 0.52
This information is updated per the most recent prospectus.

Historical Prices

 
No history records found for this date range
Date Net Asset Value ($) Public Offering Price ($)
{{histTableData.rateDate | date : 'MM/dd/yyyy'}} {{histTableData.netAssetValue | numberValue}} {{histTableData.offeringPrice | numberValue}}

Distributions

From   to
    Capital Gains Reinvestment
Price ($)
Ex-Date Income Short Term Long Term
{{distribution.rateDate | date : 'MM/dd/yyyy'}} {{distribution.dividendFactor | numberValue:4:'N/A'}} {{distribution.capGainsFactorShort | numberValue:4:'N/A'}} {{distribution.capGainsFactorLong | numberValue:4:'N/A'}} {{distribution.reinvestmentPrice | numberValue:3:'N/A'}}
as of 10/31/2022

Sector Breakdown

Holdings % of Total Net Assets
CASH/OTHER 0.75
Communication Services 4.12
Consumer Discretionary 11.02
Energy 5.26
Financials 13.59
Health Care 13.02
Industrials 14.48
Materials 5.35
Real Estate 5.61
Utilities 5.51
Information Technology 14.47
Consumer Staples 6.81

May not equal 100% due to rounding.

The holdings are organized according to the Global Industry Classification Standard, which was developed by and is the exclusive property and a service mark of Morgan Stanley Capital International Inc. and Standard & Poor's.

as of 10/31/2022

Asset Mix

Holdings % of Total Net Assets
Common Stocks 99.25
Cash 0.73
Others 0.02

May not equal 100% due to rounding.

as of 10/31/2022

Fund Characteristics

3-Year Alpha -0.52%
3-Year Beta 1.00
3-Year R-Squared 1.00
3-Year Sharpe Ratio 0.41
3-Year Standard Deviation 22.80
Number of Securities 504
Total Assets $6,289,677,674.00
Wghtd Med Mkt Cap MM$ $29,676.00

Source: RIMES Technologies Corp.,StyleADVISOR

Benchmark:  S&P 500 Equal Weight Total Return Index (USD)

as of 10/31/2022

Top Equity Holdings | View all

  % of Total Assets
Biogen 0.28
Schlumberger 0.27
Dexcom 0.27
Arch Capital 0.27
Netflix 0.26
Halliburton 0.25
PG&E 0.25
Gilead Sciences 0.25
APA 0.25
Phillips 66 0.25

May not equal 100% due to rounding.

Holdings are subject to change and are not buy/sell recommendations.

as of 10/31/2022

Top Industries

  % of Total Assets
Electric Utilities 3.17
Health Care Equipment 3.17
Packaged Foods & Meats 2.58
Semiconductors 2.55
Industrial Machinery 2.46
Regional Banks 2.44
Application Software 2.31
Oil & Gas Exploration & Production 2.27
Life Sciences Tools & Services 2.26
Aerospace & Defense 2.15

May not equal 100% due to rounding.

The holdings are organized according to the Global Industry Classification Standard, which was developed by and is the exclusive property and a service mark of Morgan Stanley Capital International Inc. and Standard & Poor's.

About risk

As with any mutual fund investment, loss of money is a risk of investing. An investment in the Fund is not a deposit in a bank and is not insured or guaranteed by the Federal Deposit Insurance Corporation or any other governmental agency. The risks associated with an investment in the Fund can increase during times of significant market volatility. The principal risks of investing in the Fund are:

Market Risk. The market values of the Fund’s investments, and therefore the value of the Fund’s shares, will go up and down, sometimes rapidly or unpredictably. Market risk may affect a single issuer, industry or section of the economy, or it may affect the market as a whole. The value of the Fund’s investments may go up or down due to general market conditions that are not specifically related to the particular issuer, such as real or perceived adverse economic conditions, changes in the general outlook for revenues or corporate earnings, changes in interest or currency rates, regional or global instability, natural or environmental disasters, widespread disease or other public health issues, war, acts of terrorism or adverse investor sentiment generally. During a general downturn in the financial markets, multiple asset classes may decline in value. When markets perform well, there can be no assurance that specific investments held by the Fund will rise in value.

Investing in Stocks Risk. The value of the Fund’s portfolio may be affected by changes in the stock markets. Stock markets may experience significant short-term volatility and may fall or rise sharply at times. Adverse events in any part of the equity or fixed-income markets may have unexpected negative effects on other market segments. Different stock markets may behave differently from each other and U.S. stock markets may move in the opposite direction from one or more foreign stock markets.

The prices of individual stocks generally do not all move in the same direction at the same time. However, individual stock prices tend to go up and down more dramatically than those of certain other types of investments, such as bonds. A variety of factors can negatively affect the price of a particular company’s stock. These factors may include, but are not limited to: poor earnings reports, a loss of customers, litigation against the company, general unfavorable performance of the company’s sector or industry, or changes in government regulations affecting the company or its industry. To the extent that securities of a particular type are emphasized (for example foreign stocks, stocks of small- or mid-cap companies, growth or value stocks, or stocks of companies in a particular industry), fund share values may fluctuate more in response to events affecting the market for those types of securities.

Index Risk. Unlike many investment companies, the Fund does not utilize an investing strategy that seeks returns in excess of its Underlying Index. Therefore, the Fund would not necessarily buy or sell a security unless that security is added to or removed from, respectively, the Underlying Index, even if that security generally is underperforming. Additionally, the Fund generally rebalances its portfolio in accordance with the Underlying Index, and, therefore, any changes to the Underlying Index’s rebalance schedule will typically result in corresponding changes to the Fund’s rebalance schedule.

Derivatives Risk. The value of a derivative instrument depends largely on (and is derived from) the value of an underlying security, currency, commodity, interest rate, index or other asset (each referred to as an underlying asset). In addition to risks relating to the underlying assets, the use of derivatives may include other, possibly greater, risks, including counterparty, leverage and liquidity risks. Counterparty risk is the risk that the counterparty to the derivative contract will default on its obligation to pay the Fund the amount owed or otherwise perform under the derivative contract. Derivatives create leverage risk because they do not require payment up front equal to the economic exposure created by holding a position in the derivative. As a result, an adverse change in the value of the underlying asset could result in the Fund sustaining a loss that is substantially greater than the amount invested in the derivative or the anticipated value of the underlying asset, which may make the Fund’s returns more volatile and increase the risk of loss. Derivative instruments may also be less liquid than more traditional investments and the Fund may be unable to sell or close out its derivative positions at a desirable time or price. This risk may be more acute under adverse market conditions, during which the Fund may be most in need of liquidating its derivative positions. Derivatives may also be harder to value, less tax efficient and subject to changing government regulation that could impact the Fund’s ability to use certain derivatives or their cost. Derivatives strategies may not always be successful. For example, derivatives used for hedging or to gain or limit exposure to a particular market segment may not provide the expected benefits, particularly during adverse market conditions.